Drugs / NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02775292 | Jan 2017 → Apr 2019 | childhood malignant neoplasm, metastatic neoplasm | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01697527 | Nov 2012 → Nov 2026 expected | cancer | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02775292 ↗ |
| Action | Deplete | “genetically reprogramming a patient's disease fighting white blood cells may build an immune response to kill cancer cells that express the NY-ESO-1 protein” NCT01697527 ↗ |
| Modality | Cell therapy | “two patient-specific cell therapies, the NY-ESO-1 TCR transgenic peripheral blood mononuclear cell (PBMC)” NCT01697527 ↗ |
| Route | Intravenous | “NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL IV” NCT01697527 ↗ |